Literature DB >> 20544233

LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Soraya Bardien1, Angelica Marsberg, Rowena Keyser, Debbie Lombard, Suzanne Lesage, Alexis Brice, Jonathan Carr.   

Abstract

Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most significant genetic cause of Parkinson's disease (PD). The exact function of LRRK2 is currently unknown but the presence of multiple protein interaction domains including WD40 and ankyrin indicates that it may act a scaffold for assembly of a multi-protein signaling complex. The G2019S mutation in LRRK2 represents the most clinically relevant PD-causing mutation and has been found in both familial and sporadic forms of the disorder. This mutation is situated in the highly conserved kinase MAPKKK domain, and has been found in up to 40% of PD patients from North African Arabic, 30% of Ashkenazi Jewish and approximately 10% of Portuguese and Spanish populations. Although extensively investigated in numerous European and North American populations, studies on the frequency of G2019S in African countries have been rare. The present study is the first on the South African population. High-resolution melt analysis was used to identify the G2019S mutation and it was found in 2% (4/205) of the patients studied. G2019S was not found in any of the Black PD patients screened. In all four G2019S-positive probands the mutation was shown to be present on the common haplotype referred to as haplotype 1. This reveals that the four South African G2019S-positive probands (three Caucasian and one of mixed ancestry) share a common ancestor with the other haplotype 1-associated families reported worldwide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544233     DOI: 10.1007/s00702-010-0423-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  38 in total

1.  Risk tables for parkinsonism and Parkinson's disease.

Authors:  Alexis Elbaz; James H Bower; Demetrius M Maraganore; Shannon K McDonnell; Brett J Peterson; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

2.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

3.  Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?

Authors:  S Lesage; S Belarbi; A Troiano; C Condroyer; N Hecham; P Pollak; E Lohman; T Benhassine; F Ysmail-Dahlouk; A Dürr; M Tazir; A Brice
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

Review 4.  High resolution melting applications for clinical laboratory medicine.

Authors:  Maria Erali; Karl V Voelkerding; Carl T Wittwer
Journal:  Exp Mol Pathol       Date:  2008-04-13       Impact factor: 3.362

5.  A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease.

Authors:  L Warren; R Gibson; L Ishihara; R Elango; Z Xue; A Akkari; L Ragone; Rajesh Pahwa; Joseph Jankovic; Martha Nance; Alan Freeman; Ray L Watts; F Hentati
Journal:  Parkinsonism Relat Disord       Date:  2007-04-11       Impact factor: 4.891

Review 6.  Leucine-rich repeat kinase 2: relevance to Parkinson's disease.

Authors:  Luxuan Guo; Wen Wang; Shu G Chen
Journal:  Int J Biochem Cell Biol       Date:  2006-03-02       Impact factor: 5.085

7.  LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.

Authors:  Suzanne Lesage; Sabine Janin; Ebba Lohmann; Anne-Louise Leutenegger; Laurence Leclere; François Viallet; Pierre Pollak; Franck Durif; Stéphane Thobois; Valérie Layet; Marie Vidailhet; Yves Agid; Alexandra Dürr; Alexis Brice; Anne-Marie Bonnet; Michel Borg; Emmanuel Broussolle; Philippe Damier; Alain Destée; Maria Martinez; Christiane Penet; Olivier Rasco; François Tison; Christine Tranchan; Marc Vérin
Journal:  Arch Neurol       Date:  2007-03

Review 8.  Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.

Authors:  Cíntia B Santos-Rebouças; Cláudia B Abdalla; Fábio José R Baldi; Paloma A Martins; Juliana C Corrêa; Andressa P Gonçalves; Marcela S Cunha; Margarete B Borges; João S Pereira; Jerson Laks; Márcia M G Pimentel
Journal:  Genet Test       Date:  2008-12

9.  LRRK2 R1628P increases risk of Parkinson's disease: replication evidence.

Authors:  E K Tan; Louis C Tan; H Q Lim; R Li; M Tang; Yuen Yih; R Pavanni; K M Prakash; S Fook-Chong; Yi Zhao
Journal:  Hum Genet       Date:  2008-09-10       Impact factor: 4.132

Review 10.  The Roco protein family: a functional perspective.

Authors:  Ignacio Marín; Wouter N van Egmond; Peter J M van Haastert
Journal:  FASEB J       Date:  2008-06-03       Impact factor: 5.191

View more
  14 in total

1.  Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana.

Authors:  Roberto Cilia; Francesca Sironi; Albert Akpalu; Momodou Cham; Fred Stephen Sarfo; Tiziana Brambilla; Alba Bonetti; Marianna Amboni; Stefano Goldwurm; Gianni Pezzoli
Journal:  J Neurol       Date:  2011-08-14       Impact factor: 4.849

2.  Identification of Parkinson's disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson's disease patients.

Authors:  Rowena J Keyser; Ekow Oppon; Jonathan A Carr; Soraya Bardien
Journal:  J Neural Transm (Vienna)       Date:  2011-02-23       Impact factor: 3.575

3.  Neurexin 2 p.G849D variant, implicated in Parkinson's disease, increases reactive oxygen species, and reduces cell viability and mitochondrial membrane potential in SH-SY5Y cells.

Authors:  Katelyn Cuttler; Dalene de Swardt; Lize Engelbrecht; Jurgen Kriel; Ruben Cloete; Soraya Bardien
Journal:  J Neural Transm (Vienna)       Date:  2022-10-15       Impact factor: 3.850

4.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

5.  Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease.

Authors:  Nicola du Toit; Riaan van Coller; David G Anderson; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2019-09-06       Impact factor: 2.660

Review 6.  Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.

Authors:  Rufus O Akinyemi; Mayowa O Owolabi; Tolulope Oyeniyi; Bruce Ovbiagele; Donna K Arnett; Hemant K Tiwari; Richard Walker; Adesola Ogunniyi; Raj N Kalaria
Journal:  J Neurol Sci       Date:  2016-05-06       Impact factor: 3.181

Review 7.  Neuroscience-related research in Ghana: a systematic evaluation of direction and capacity.

Authors:  Emmanuel Quansah; Thomas K Karikari
Journal:  Metab Brain Dis       Date:  2015-09-07       Impact factor: 3.584

8.  A molecular analysis of the GBA gene in Caucasian South Africans with Parkinson's disease.

Authors:  Melinda Barkhuizen; David G Anderson; Francois H van der Westhuizen; Anne F Grobler
Journal:  Mol Genet Genomic Med       Date:  2017-02-08       Impact factor: 2.183

9.  Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice.

Authors:  Emilie Giaime; Youren Tong; Lisa K Wagner; Yang Yuan; Guodong Huang; Jie Shen
Journal:  Neuron       Date:  2017-10-19       Impact factor: 17.173

10.  Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.

Authors:  Selma Yılmazer; Esin Candaş; Gençer Genç; Merve Alaylıoğlu; Büşra Şengül; Ayşegül Gündüz; Hülya Apaydın; Güneş Kızıltan; Sibel Ertan; Erdinç Dursun; Duygu Gezen-Ak
Journal:  Neuromolecular Med       Date:  2020-10-04       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.